|
| FDA Approves Advair(R) 250/50 For Reduction Of Exacerbations In Patients With COPD |
1 May 08, 08:09 |
|
| The U.S. Food and Drug Administration approved Advair Diskus(R) 250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations. With this approval, Advair becomes the only treatment FDA has approved to reduce COPD exacerbations. |
| more |
|
